Diary - News
All news French biopharmaceutical company Fab’entech launches production of its Ebola treatment
Fab’entech, specialized in treatments against emerging infectious diseases since 2009, proposes anti-infective passive immunotherapy solutions based on highly purified specific polyclonal antibodies.
In collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA) and with its excellent reputation for production capacity, short development delays and high product quality, Fab’entech accelerated its project to develop an emergency solution to the ongoing public health issue of Ebola.
